Corbevax, India's first indigenously developed protein sub-unit vaccine against Covid-19, has been developed by Biological E in collaboration with Texas Children's Hospital Center for Vaccine ...

Biological E has sought emergency use authorisation from India's drug regulator for its COVID-19 vaccine Corbevax for the 12 to 18 years age group, official sources said on Sunday. The Drugs ...

New Delhi: The first supply of 300 million doses of Biological E’s Covid-19 vaccine, Corbevax, is set to start from Tuesday, said a report. Speaking to the Business Standard, a senior government ...

GSK has announced a 50/50 joint venture with leading Indian vaccines company, Biological E, for the early stage research and development of a six-in-one combination paediatric vaccine to help ...

According to respective company sources, Biological E is holding 200 million doses ... The company said 14-valent paediatric Pneumococcal Conjugate Vaccine (PCV14) against S.

Sinergium won the contract and, in 2010, began building a state-of-the-art facility capable of producing vaccines and other biological ... Pfizer for a 13-valent pneumococcal conjugate vaccine ...

The vaccine showed promising results in clinical trials. Although the prevention of pneumonia caused by specific pneumococcal ...

You have a good eye. This past fall, the Centers for Disease Control and Prevention changed the recommended age for getting the vaccine for pneumococcal pneumonia from those 65 and older to those ...

The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for the pneumococcal vaccine Capvaxive (pneumococcal polysaccharide conjugate vaccine [21-valent]) intended to ...